[{"id":"67594d86-d6cf-4b01-aefe-6548477c2d62","acronym":"EMR100018-001","url":"https://clinicaltrials.gov/study/NCT01971515","created_at":"2021-01-18T08:58:11.943Z","updated_at":"2024-07-02T16:37:06.726Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01971515 - EMR100018-001","lead_sponsor":"EMD Serono","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • rupitasertib (DIACC3010)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-09-19"}]